Genetic Therapy Shows Promise in Halting ALS
The CTx1000, a single-dose genetic medication, targets pathological accumulations of the TDP-43 protein, offering hope for treating various forms of dementia.
Stay updated with breaking news from Lars Ittner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The CTx1000, a single-dose genetic medication, targets pathological accumulations of the TDP-43 protein, offering hope for treating various forms of dementia.
Neuroscientists at Macquarie University in Australia have developed a single-dose genetic medicine that has been proven to halt the progression of both ALS and frontotemporal dementia (FTD) in mice – and may even offer the potential to reverse some of the effects of the fatal diseases.
Neuroscientists at Macquarie University in Australia have developed a single-dose genetic medicine that has been proven to halt the progression of both ALS and
Scientists across the globe have tried and failed to translate treatments for motor neuron disease from mice to humans. A Sydney team is aiming to be the first.
Scientists across the globe have tried and failed to translate treatments for motor neuron disease from mice to humans. A Sydney team is aiming to be the first.